Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG

Phase 1

Completed

• Conditions: Non-Hodgkin's Lymphoma; Lymphoma, B-Cell

• Registration Number: NCT00061425
• Lead Sponsor: Gilead Sciences

Brief Summary

The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-08
• Study First Submitted: 2003-05-27
• Study First Submitted QC: 2003-05-27
• Study First Posted: 2003-05-28
• Primary Completion: 2007-11
• Status Verified: 2009-01
• Last Update Submitted: 2021-08-12
• Last Update Posted: 2021-08-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP